A private Turkish hospital group whose Istanbul site states it runs an in-house cellular therapy unit preparing stem cell, exosome and bone marrow products.
Liv Hospital is a private hospital group in Turkey. According to its own website, its regenerative medicine and stem cell work is based at Liv Hospital Ulus in Istanbul, with further branches named at Vadistanbul, Bahcesehir and Topkapi in Istanbul and one in Ankara. The site gives 444 4 548 as its central appointment number and +90 530 174 42 01 as a line for international enquiries. The group's own hospital listing also names Liv Hospital Samsun, Liv Hospital Gaziantep and Liv Bona Dea Hospital in Baku, Azerbaijan. No street address is published for the cell unit itself.
The hospital states that it operates its own cellular therapy unit, which it calls LivMedCell, and describes it as a cellular treatment centre run within hospital conditions. The site says the unit works to Good Manufacturing Practice standards, which is the quality framework used for the manufacture of medicinal products. The site does not publish the details of any licence or the name of the authority that granted it, and these claims have not been independently checked for this listing.
The site lists the cell preparations it says the unit produces. These include mesenchymal stem cells, a type of cell that can be isolated from several tissues, drawn from umbilical cord, adipose (fat) tissue, cartilage tissue and synovial tissue; fibroblasts taken from skin tissue; exosomes, which the site describes as small particles released by cells; adipose-derived stromal vascular fraction, a mixed cell preparation obtained from fat tissue; and bone marrow-derived mononuclear cells.
A separate page on the site lists the conditions it associates with stem cell work. Many of these are blood and bone marrow disorders for which bone marrow transplantation is long-established hospital treatment, such as the leukaemias, aplastic anaemia, lymphoma, multiple myeloma, myelodysplastic syndrome, myelofibrosis, sickle cell disease and thalassaemia. The same list also names orthopaedic injury and cartilage degeneration, which are not transplant indications. Readers should note that listing these together may give the impression that evidence from bone marrow transplantation supports cell injections for joint problems; the site does not draw that distinction. No outcome figures are published on the pages reviewed.
Two different sets of conditions appear under the hospital's stem cell heading, and they are not the same kind of medicine. The first group is the list of licensed indications its own cell unit publishes. The second is a list of blood and bone marrow disorders that appears only on the group's international site, and which is treated by bone marrow transplantation — long-established hospital medicine, and not evidence for the cell injections in the first group. Naming a condition is not evidence that treatment helps it.
The site states that the hospital prepares its own cell products in a dedicated unit within the hospital and that it uses adult cells rather than embryonic ones.
One clinician is named on the site in connection with the stem cell unit.
The site describes the cellular therapy unit as sitting inside the hospital rather than in a separate laboratory, and calls it a cellular treatment centre operating in hospital conditions to Good Manufacturing Practice standards. The main regenerative medicine site is given as Liv Hospital Ulus in Istanbul, with further hospitals in the group named at Vadistanbul, Bahcesehir and Topkapi in Istanbul and at Ankara. The pages reviewed do not print a street address for any branch.
The pages reviewed give no prices and no price ranges. The site directs enquiries to its international patient and second opinion services instead.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.